Professor Michael Tatley
| Position | Director, New Zealand Pharmacovigilance Centre |
|---|---|
| Qualifications | MB ChB(CapeTown) FFCM(SA) |
| Research summary | Monitoring adverse reactions medicines |
Research
Professor Tatley is Director of the New Zealand Pharmacovigilance Centre.
The New Zealand Pharmacovigilance Centre consists of the Centre for Adverse Reactions Monitoring (CARM) and the The Intensive Medicines Monitoring Programme (IMMP).
Adverse reaction reporting is an important component of New Zealand's pharmacovigilance activities. The Centre for Adverse Reactions Monitoring (CARM) in Dunedin is New Zealand's national monitoring centre for adverse reactions. It collects and evaluates spontaneous reports of adverse reactions to medicines, vaccines, herbal products and dietary supplements from health professionals in New Zealand. Currently the CARM database holds over 50,000 reports and provides New Zealand-specific information on adverse reactions to these products, and serves to support clinical decision making when unusual symptoms are thought to be therapy related.
The Intensive Medicines Monitoring Programme undertakes prospective, observational, cohort studies on selected new medicines. These are aimed at measuring the incidence of adverse reactions, their characterisation, the early identification of previously unrecognised reactions and the construction of a risk profile for each medicine. The results are reported to the Ministry of Health and the health professions. It has a considerable international reputation.
Publications
Ameratunga, R., Woon, S.-T., Sheppard, M. N., Garland, J., Ondruschka, B., Wong, C. X., … Tatley, M., … Tse, R. D. (2022). First identified case of fatal fulminant necrotizing eosinophilic myocarditis following the initial dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): An extremely rare idiosyncratic hypersensitivity reaction. Journal of Clinical Immunology, 42, 441-447. doi: 10.1007/s10875-021-01187-0
Bennett, M., Chang, C. L., Tatley, M., Savage, R., & Hancox, R. J. (2021). The safety of cardio-selective beta1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports. ERJ Open Research, 7, 1-10. doi: 10.1183/23120541.00801-2020
Robson, H., Braund, R., Glass, M., Ashton, J., & Tatley, M. (2021). Synthetic cannabis: Adverse events reported to the New Zealand Pharmacovigilance Centre. Clinical Toxicology, 59(6), 472-479. doi: 10.1080/15563650.2020.1828592
Savage, R. L., Hill, G. R., Barnes, J., Kenyon, S. H., & Tatley, M. V. (2019). Suspected hepatotoxicity with a supercritical carbon dioxide extract of Artemisia annua in grapeseed oil used in New Zealand [Brief research report article]. Frontiers in Pharmacology, 10, 1448. doi: 10.3389/fphar.2019.01448
Savage, R. L., & Tatley, M. V. (2018). Case series analysis of New Zealand reports of rapid intense potentiation of warfarin by roxithromycin [Short communcation]. Drug Safety, 41(5), 515-521. doi: 10.1007/s40264-017-0634-y
Ministry of Health, including Chambers, S., Jennings, L., & Tatley, M. (2006). Immunisation Handbook 2006. Wellington, New Zealand: Ministry of Health, 455p.
Authored Book - Research
Harrison-Woolrych, M., Tatley, M., & Kunac, D. (2014). Pharmacovigilance in New Zealand. In E. B. Andrews & N. Moore (Eds.), Mann's pharmacovigilance. (3rd ed.) (pp. 291-294). Chichester, UK: Wiley Blackwell. doi: 10.1002/9781118820186.ch16a
Chapter in Book - Research
Ameratunga, R., Woon, S.-T., Sheppard, M. N., Garland, J., Ondruschka, B., Wong, C. X., … Tatley, M., … Tse, R. D. (2022). First identified case of fatal fulminant necrotizing eosinophilic myocarditis following the initial dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): An extremely rare idiosyncratic hypersensitivity reaction. Journal of Clinical Immunology, 42, 441-447. doi: 10.1007/s10875-021-01187-0
Journal - Research Article
Robson, H., Braund, R., Glass, M., Ashton, J., & Tatley, M. (2021). Synthetic cannabis: Adverse events reported to the New Zealand Pharmacovigilance Centre. Clinical Toxicology, 59(6), 472-479. doi: 10.1080/15563650.2020.1828592
Journal - Research Article
Kunac, D. L., Tatley, M. V., & Seddon, M. E. (2014). A new web-based Medication Error Reporting Programme (MERP) to supplement pharmacovigilance in New Zealand: Findings from a pilot study in primary care. New Zealand Medical Journal, 127(1401). Retrieved from http://www.nzma.org.nz/journal
Journal - Research Article
Holst, J., Oster, P., Arnold, R., Tatley, M. V., Næss, L. M., Aaberge, I. S., … Black, S. (2013). Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future. Human Vaccines & Immunotherapeutics, 9(6), 1241-1253. doi: 10.4161/hv.24129
Journal - Research Article
Kunac, D. L., & Tatley, M. V. (2011). Detecting medication errors in the New Zealand Pharmacovigilance Database: A retrospective analysis. Drug Safety, 34(1), 59-71. doi: 10.2165/11539290-000000000-00000
Journal - Research Article
Kunac, D. L., Harrison-Woolrych, M., & Tatley, M. V. (2008). Pharmacovigilance in New Zealand: The role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. New Zealand Medical Journal, 121(1283). Retrieved from http://journal.nzma.org.nz/journal/121-1283/3286/content.pdf
Journal - Research Article
Tatley, M. V., Kunac, D. L., McNicholas, A., Zhou, L., Ballantyne, S., Ashton, J., … Reid, S. (2008). The Intensive Vaccines Monitoring Programme (IVMP): An electronic system to monitor vaccine safety in New Zealand. Vaccine, 26(22), 2746-2752. doi: 10.1016/j.vaccine.2008.03.017
Journal - Research Article
McNicholas, A., Galloway, Y., Stehr-Green, P., Reid, S., Radke, S., Sexton, K., … Tatley, M., … O'Hallahan, J. (2007). Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Human Vaccines, 3(5), 196-204.
Journal - Research Article
Tatley, M., & Savage, R. (2007). Psychiatric adverse reactions with statins, fibrates and ezetimibe: Implications for the use of lipid-lowering agents. Drug Safety, 30(3), 195-201.
Journal - Research Article
Tatley, M. V. (2002). The monitoring of adverse events following immunisation. New Zealand Medical Journal, 115(1165).
Journal - Research Article
Zwarenstein, M., Schoeman, J. H., Vandule, C., Lombard, C. J., & Tatley, M. (1998). Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet, 352(9137), 1340-1343.
Journal - Research Article
Bennett, M., Chang, C. L., Tatley, M., Savage, R., & Hancox, R. J. (2021). The safety of cardio-selective beta1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports. ERJ Open Research, 7, 1-10. doi: 10.1183/23120541.00801-2020
Journal - Research Other
Savage, R. L., Hill, G. R., Barnes, J., Kenyon, S. H., & Tatley, M. V. (2019). Suspected hepatotoxicity with a supercritical carbon dioxide extract of Artemisia annua in grapeseed oil used in New Zealand [Brief research report article]. Frontiers in Pharmacology, 10, 1448. doi: 10.3389/fphar.2019.01448
Journal - Research Other
Savage, R. L., & Tatley, M. V. (2018). Case series analysis of New Zealand reports of rapid intense potentiation of warfarin by roxithromycin [Short communcation]. Drug Safety, 41(5), 515-521. doi: 10.1007/s40264-017-0634-y
Journal - Research Other
Savage, R. L., Castellano, M., & Tatley, M. V. (2017). International reports of unexpected low plasma concentrations of dabigatran suggest that more frequent measurements will add value. Seminars in Thrombosis & Hemostasis, 43(6), 635-638. doi: 10.1055/s-0037-1603361
Journal - Research Other
Kunac, D., Tatley, M. V., Grimwood, K., & Reith, D. M. (2012). Active surveillance of serious adverse drug reactions in New Zealand children. Archives of Disease in Childhood, 97(8), 761-762. doi: 10.1136/archdischild-2011-301457
Journal - Research Other
Tatley, M. (2009). Monitoring of generic medicines and brand changes. Best Practice Journal, (July), 18-20.
Journal - Research Other
Barnes, J., & Tatley, M. (2007). Scant reporting on CAMs safety in NZ. Pharmacy Today, (February), 6.
Journal - Research Other
Savage, R., & Tatley, M. (2004). Myopathy with statins: Check CK levels and interactions. Prescriber Update, 25(1), 4-5. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp
Journal - Research Other
Tatley, M. (2002). Pulmonary reactions with nitrofurantoin. Prescriber Update, 23(2), 24-25. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp
Journal - Research Other
Tatley, M. (2001). Bupropion (ZybanTM) for second-line treatment only. Prescriber Update, 22, 4-8. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp
Journal - Research Other
Tatley, M. (2001). Ticlopidine, Clopidogrel and Thrombotic Thrombocytopenic Purpura. Prescriber Update, 20, 19-21. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp
Journal - Research Other
Tatley, M. (2001). Your guide to adverse reaction reporting. Prescriber Update, 22, 21-25. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp
Journal - Research Other
Zwarenstein, M., Shoeman, J. H., Vundule, C., Lombard, C. J., & Tatley, M. V. (2000). A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. International Journal of Tuberculosis & Lung Disease, 4(6), 550-554.
Journal - Research Other
